A Study of MK0777 in the Treatment of Outpatients With Generalized Anxiety Disorder (0777-020)

• Status: Completed
• Trial end date: 2003-02-01
• Target enrollment: 0
• Participant gender: All

Summary

The study will look at the effect of MK0777on reducing anxiety in subjects with general anxiety disorder.

This is an early phase trial and some specific protocol information is in progress and not publicly available at this time. (Full information is available to trial participants).

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Merck Sharp & Dohme Corp.

Criteria

Inclusion Criteria:

• Diagnosis of General Anxiety Order

Exclusion Criteria:

• Women who are pregnant or breast-feeding

• History of severe drug reaction

• History of severe drug withdrawal symptoms such as seizures or delirium

• Disease of cardiovascular system

• Disease of the liver, kidneys, endocrine system, metabolic system or eyes

• History of seizures or seizure disorder

• History of drug or alcohol abuse